Daniel J. Brennan filed an initial statement of beneficial ownership with the SEC on October 22, 2026, disclosing his status as a newly appointed director of Vertex Pharmaceuticals Incorporated, traded on NASDAQ:VRTX.

Key Highlights

  • Reporting person: Daniel J. Brennan, identified as a director of Vertex Pharmaceuticals Incorporated.
  • Event date: The date of the event requiring the statement was October 20, 2026.
  • Filing date: The statement was signed and filed on October 22, 2026, by Christiana Stevenson as attorney-in-fact.
  • No securities owned: According to the filing, "No securities are beneficially owned" by the reporting person at the time of the statement.
  • Filing type: This is an initial statement, filed by one reporting person, and is not an amendment to a prior filing.

Brennan's Initial Ownership Disclosure at Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biopharmaceutical company headquartered at 50 Northern Avenue in Boston, Massachusetts, received an initial beneficial ownership statement from Daniel J. Brennan following his appointment to the company's board of directors. The triggering event was recorded as October 20, 2026, two days before the statement was formally submitted to the SEC.

According to the filing, Brennan reported no beneficial ownership of any class of Vertex securities at the time of the statement, with both Table I (covering non-derivative securities) and Table II (covering derivative securities such as options, warrants, and convertible instruments) left blank. The filing states explicitly that "No securities are beneficially owned." The statement was executed by Christiana Stevenson under a power of attorney, as referenced by Exhibit 24 attached to the filing.

Brennan filed the statement individually, rather than as part of a joint or group filing. The issuer is listed as Vertex Pharmaceuticals Inc / MA, with the trading symbol VRTX on the NASDAQ exchange.

What Was Disclosed

Daniel J. Brennan submitted an initial beneficial ownership statement upon joining the board of directors of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The filing, dated October 22, 2026, reported no direct or indirect beneficial ownership of any Vertex securities, derivative or otherwise, as of the October 20, 2026 event date.